Business
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical data for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers - Poster presentations on preclinical data for Selective CBP degrader in combination with chemotherapy and targeted agents and for Selective EP300 degrader in hematological malignancies
About this update from Foghorn Therapeutics Inc.
[{"type":"image","alt":"Foghorn Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Foghorn Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ql7RNPJuQ1jhwreokk4ggw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086","width":300,"height":75}},"lazy":false},{"type":"text","content":"- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population","length":167,"tagName":"p"},{"type":"text","content":"- Oral presentation on preclinical data for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers","length":146,"tagName":"p"},{"type":"text","content":"- Poster presentations on preclinical data for Selective CBP degrader in combination with chemotherapy and targeted agents and for Selective EP300 degrader in hematological malignancies ","length":185,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical combination data for FHD-909, a potential first-in-class selective SMARCA2 inhibitor will be presented as an oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025, in Chicago, Illinois. Poster presentations on the Phase 1 trial design for FHD-909 and on preclinical data for the Selective CBP program and the Selective EP300 degrader program will also be presented.","length":709,"tagName":"p"},{"type":"text","content":"“We are excited to share new preclinical data at this year’s AACR conference further strengthening the promise of our differentiated programs,” said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. “Importantly, enrollment and dose escalation are on track in the ongoing Phase 1 trial evaluating FHD-909, a first-in-class oral selective SMARCA2 inhibitor, in SMARCA4 mutated ...